Type 1 growth factor receptor expression in node positive breast cancer: Adverse prognostic significance of c-erbB-4

Journal of Clinical Pathology

Volumn 56, Issue 4, 2003, Pages 300-304

  Lodge, A J ^a   Anderson, J J ^a   Gullick, W J ^b   Haugk, B ^a   Leonard, R C F ^c   Angus, B ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

^c SINGLETON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C ERBB 3 RECEPTOR; C ERBB 4 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0344511811     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.4.300     Document Type: Article

References (22)

1. Galea MH, Blamey RW, Elston CE, et al. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-19.
2. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 1998;52:43-53.
3. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein - a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90.
4. Clark GM. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J Natl Cancer Inst 1998;90:1320-1.
5. Dillman RO. Perceptions of Herceptin(R): a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm 1999;14:5-10.
6. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95.
7. Moasser MM, Basso A, Averbuch SD, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
8. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-8.
9. Torregrosa D, Bolufer P, Lluch A, et al. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 1997;262:99-119.
10. Klijn JGM, Berns P, Schmitz PIM, et al. The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer - a review of 5232 patients. Endocr Rev 1992;13:3-17.
11. Travis A, Pinder SE, Robertson JFR, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996;74:229-33.
12. Lemoine NR, Barnes DM, Hollywood DP, et al. Expression of the erbB-3 gene product in breast cancer. Br J Cancer 1992;66:1116-21.
13. Quinn CM, Ostrowski JL, Lane SA, et al. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 1994;25:247-52.
14. Kew TY, Bell JA, Pinder SE, et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer 2000;82:1163-70.
15. Srinivasan R, Gillett CE, Barnes DM, et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 2000;60:1483-7.
16. Naidu R, Yadav M, Nair S, et al. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998;78:1385-90.
17. Suo Z, Berner HS, Risberg B, et al. Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 2001;439:62-9.
18. Knowlden JM, Gee JMW, Seery LT, et al. C-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998;17:1949-57.
19. Pawlowski V, Revillion F, Hebbar M, et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:4217-25.
20. Detre S, Jotti GS, Dowsett M. A quickscore method for immunohistochemical semiquantitation - validation for estrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.
21. Jarvinen TAH, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.
22. Merimsky O, Staroselski A, Inbar M, et al. Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non small cell lung cancer. Ann Oncol 2001;12:1127-31